BACKGROUND Excessive maturation of hematopoietic cells leads to a reduction of long-term proliferative capability during cord blood (CB) expansion. In this study, we report the effects of anit-CD52 (Alemtuzumab, Campath) on both short- and long-term ex vivo expansion of CB hematopoietic stem cells (HSC) by evaluating the potential role of Alemtuzumab in preserving the repopulating capability in...

Alemtuzumab is a humanized monoclonal antibody directed against CD52, a non-modulating glycosylated peptide antigen that is highly expressed on B-cell in chronic lymphocytic leukemia (CLL) and on normal lymphocytes. CD52 is expressed on virtually all lymphocytes at various stages of differentiation, as well as on monocytes, macrophages and eosinophils; it is not expressed on granulocytes (<5%) ...

Multiple sclerosis (MS) is among the most common chronic inflammatory diseases of the central nervous system. Although not curable, the constantly increasing armamentarium of disease-modifying drugs now allows control of disease activity in many patients. The humanized monoclonal antibody alemtuzumab is a powerful drug licensed for the treatment of MS. Upon binding to the CD52 surface protein o...

Background: Systemic sclerosis (SSc) is associated with an interferon (IFN) signature, which defined by a higher expression of IFN-stimulated genes (mainly in response to IFNα). Histone deacetylases (HDACs) are family epigenetic modifiers mediating immune function. HDACs function via diverse molecular mechanisms, including direct inhibition gene transcription or indirectly through modulation nu...